← Back to Home

Helping Cancer-Fighting T Cells Last Longer: CRISPR Screen Identifies CRL5 as a Target for Regulating Exhaustion

Immune cells may gradually lose their fighting capacity after repeated encounters with tumors. A UCLA study found that disrupting components of the CRL5 complex could improve sustained function in engineered T cells and tumor control in mice, offering a new lead for cell therapies for solid tumors; whether patients can benefit awaits clinical validation.

By SURL BioNews

Delivering T cells that can recognize cancer cells into the body is only the starting point for cell therapy. With prolonged, repeated stimulation from tumors, these cells may gradually become exhausted, weakening their ability to sustain an attack. A research team at the University of California, Los Angeles (UCLA) has now identified a regulatory lead: disrupting a protein complex called CRL5 can help engineered T cells maintain better anticancer function in preclinical experiments.

The study, with Justin D. Saco as first author and Antoni Ribas as senior author, was published in *Cancer Immunology Research*. The team conducted a genome-wide CRISPR screen in human CD8⁺ T cells capable of recognizing a melanoma antigen, switching off thousands of genes individually and then repeatedly exposing the cells to tumor cells to identify genetic changes that helped them survive and keep fighting.

Repeated challenges were central to this experimental approach. Strong activity after a single brief encounter with a tumor does not necessarily mean that T cells can withstand prolonged stimulation. The screen revealed consistent signals from multiple CRL5 components across different experiments and time points, shifting the research focus from an individual gene to this ubiquitin ligase complex, which participates in cellular protein degradation and recycling.

After CRL5-related genes were disrupted, T cells retained stronger killing capacity under repeated tumor exposure, produced more immune signaling molecules, and showed fewer molecular features associated with exhaustion. In subsequent mouse models of human melanoma, animals receiving CRL5-deficient T cells had better tumor control than the control group receiving conventional engineered T cells.

The team also explored a drug-based intervention. MLN4924 can block the activation of Cullin-RING ligases, including CRL5, and partially reproduced the functional improvements from gene disruption in the laboratory. However, its activity extends to multiple ligases, so this result cannot be directly interpreted as evidence of selective CRL5 inhibition, nor can it yet establish an appropriate way to use the drug in patients.

The same journal also published a companion paper by Stefanie Bachl and colleagues from Julia Carnevale’s research team at the University of California, San Francisco, examining the relationship between CRL5 disruption and the persistence of engineered T cells under chronic tumor antigen stimulation. Medical Xpress listed information on both papers; its report and the content published by Newswise were both provided by UCLA, so these media publications do not themselves constitute additional independent validation.

For cell therapies for solid tumors, this work proposes a direction for cell engineering that can be tested further. The current evidence comes from cultured cells and mice, with no patient efficacy results yet reported. Whether T cells can maintain their function over the long term in the human body after disruption of this protein regulatory system, whether this carries safety costs, and whether the effects extend to other tumors and cell therapies are all questions that must be answered before moving into clinical testing.

References

  1. UCLA Health
  2. Medical Xpress
  3. Newswise / UCLA Health Sciences